指南与共识药物不良反应与药物警戒特殊人群用药

儿童药物警戒:药物研发中的方法学考量——c4c专家组白皮书

c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper.
指南 / 共识 · Br J Clin Pharmacol · 2021-12-18

儿童对治疗的反应常与成人不同,且不同年龄组在药代动力学和药效学上存在差异。c4c项目专家组针对儿童药物全生命周期中的药物警戒方法学提出实践要点,涵盖风险管理计划儿科部分、方案开发中的安全性、数据收集分析、上市后药物警戒、获益-风险评估及信号检测等。

要点

  • 儿童药物警戒需考虑药物反应、生长发育、不良反应临床表现及超说明书用药等独特因素。
  • 白皮书提供儿童风险管理计划、方案开发、安全性数据收集与分析及儿科研究计划中的实践要点。
  • 上市后药物警戒可利用自发报告、电子健康记录、登记系统和记录链接等方法。

核心结论

  • c4c专家组提出儿童药物警戒全生命周期的方法学考量,为风险管理计划、方案开发、安全性数据收集分析和儿科研究计划提供实践要点。

研究设计与样本

  • c4c项目框架下成立专家组,协作制定儿童药物安全与药物警戒方法学考量,以白皮书形式呈现。

主要发现

  • 儿童与成人及不同儿科年龄组在药代动力学和药效学上存在疗效与安全性差异。
  • 儿童药物警戒需理解药物反应、生长发育、不良反应临床表现、检测方式及人群特异性因素(如更频繁使用超说明书/未许可药物)。
  • 方法学考量涵盖风险管理计划儿科部分、方案开发中的安全性、安全性数据收集与分析。
  • 上市后药物警戒包括自发报告、电子健康记录、登记系统和记录链接,以及儿科药物流行病学研究用于风险表征。
  • 还涉及儿科研究计划背景下的获益-风险评估、制剂挑战及信号检测与评价的实践问题。

临床怎么用

  • 在儿童药物研发全生命周期中,参考白皮书要点制定儿科风险管理计划、方案开发、安全性数据收集分析及儿科研究计划。
  • 上市后药物警戒可综合利用自发报告、电子健康记录、登记系统和记录链接等方法。
  • 开展儿科药物流行病学研究以支持风险表征,并进行获益-风险评估和信号检测评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children frequently respond differently to therapies compared to adults. Differences also exist between paediatric age groups for pharmacokinetics and pharmacodynamics in both efficacy and safety. Paediatric pharmacovigilance requires an understanding of the unique aspects of children with regard to, for example, drug response, growth and development, clinical presentation of adverse drug reactions (ADRs), how they can be detected and population-specific factors (e.g., more frequent use of off-label/unlicensed drugs). In recognition of these challenges, a group of experts has been formed in the context of the conect4children (c4c) project to support paediatric drug development. This expert group collaborated to develop methodological considerations for paediatric drug safety and pharmacovigilance throughout the life-cycle of medicinal products which are described in this article. These considerations include practical points to consider for the development of the paediatric section of the risk management plan (RMP), safety in paediatric protocol development, safety data collection and analysis. Furthermore, they describe the specific details of post-marketing pharmacovigilance in children using, for example, spontaneous reports, electronic health care records, registries and record-linkage, as well as the use of paediatric pharmacoepidemiology studies for risk characterisation. Next the details of the assessment of benefit-risk and challenges related to medicinal product formulation in the context of a Paediatric Investigation Plan (PIP) are presented. Finally, practical issues in paediatric signal detection and evaluation are included. This paper provides practical points to consider for paediatric pharmacovigilance throughout the life-cycle of medicinal products for RMPs, protocol development, safety data collection and analysis and PIPs.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Aurich B, Apele-Freimane D, Banaschewski T, et al. c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper. Br J Clin Pharmacol. 2021. PMID: 34699077. doi:10.1111/bcp.15119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。